Global Hormone Refractory Prostate Cancer (HRPCA) Market Insights and Forecast to 2028

Report ID: 1802781 | Published Date: Jan 2025 | No. of Page: 78 | Base Year: 2024 | Rating: 4.7 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Cytotoxic Agents
        1.2.3 Anti-Androgens
        1.2.4 Vaccines
        1.2.5 Radio-Pharmaceuticals
    1.3 Market by Application
        1.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospitals
        1.3.3 Ambulatory Surgical Centers
        1.3.4 Specialty Clinics
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Perspective (2017-2028)
    2.2 Hormone Refractory Prostate Cancer (HRPCA) Growth Trends by Region
        2.2.1 Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Region (2017-2022)
        2.2.3 Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Region (2023-2028)
    2.3 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics
        2.3.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
        2.3.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
        2.3.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
        2.3.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue
        3.1.1 Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Revenue (2017-2022)
        3.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Players (2017-2022)
    3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Hormone Refractory Prostate Cancer (HRPCA) Revenue
    3.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio
        3.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2021
    3.5 Hormone Refractory Prostate Cancer (HRPCA) Key Players Head office and Area Served
    3.6 Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
    3.7 Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Type
    4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Type (2017-2022)
    4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2023-2028)
5 Hormone Refractory Prostate Cancer (HRPCA) Breakdown Data by Application
    5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size by Application (2017-2022)
    5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2017-2028)
    6.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
        6.2.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
        6.2.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028)
        6.2.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2017-2028)
    6.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
        6.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
        6.3.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028)
        6.3.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2017-2028)
    6.4 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
        6.4.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022)
        6.4.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size (2017-2028)
    7.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
        7.2.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
        7.2.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028)
        7.2.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2017-2028)
    7.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
        7.3.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
        7.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028)
        7.3.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2017-2028)
    7.4 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
        7.4.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022)
        7.4.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size (2017-2028)
    8.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
        8.2.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028)
        8.2.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2017-2028)
    8.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
        8.3.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028)
        8.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2017-2028)
    8.4 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region
        8.4.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2023-2028)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size (2017-2028)
    9.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
        9.2.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
        9.2.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028)
        9.2.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2017-2028)
    9.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
        9.3.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
        9.3.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028)
        9.3.3 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2017-2028)
    9.4 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
        9.4.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022)
        9.4.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size (2017-2028)
    10.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
        10.2.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028)
        10.2.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2017-2028)
    10.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
        10.3.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028)
        10.3.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2017-2028)
    10.4 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country
        10.4.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Astellas Inc
        11.1.1 Astellas Inc Company Details
        11.1.2 Astellas Inc Business Overview
        11.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Introduction
        11.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
        11.1.5 Astellas Inc Recent Developments
    11.2 Sanofi S.A
        11.2.1 Sanofi S.A Company Details
        11.2.2 Sanofi S.A Business Overview
        11.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Introduction
        11.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
        11.2.5 Sanofi S.A Recent Developments
    11.3 Dendreon Corporation, Bayer AG
        11.3.1 Dendreon Corporation, Bayer AG Company Details
        11.3.2 Dendreon Corporation, Bayer AG Business Overview
        11.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Introduction
        11.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
        11.3.5 Dendreon Corporation, Bayer AG Recent Developments
    11.4 Johnson & Johnson
        11.4.1 Johnson & Johnson Company Details
        11.4.2 Johnson & Johnson Business Overview
        11.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Introduction
        11.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
        11.4.5 Johnson & Johnson Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer

List of Tables
    Table 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
    Table 2. Key Players of Cytotoxic Agents
    Table 3. Key Players of Anti-Androgens
    Table 4. Key Players of Vaccines
    Table 5. Key Players of Radio-Pharmaceuticals
    Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
    Table 7. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2017-2022)
    Table 10. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region (2023-2028)
    Table 12. Hormone Refractory Prostate Cancer (HRPCA) Market Trends
    Table 13. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers
    Table 14. Hormone Refractory Prostate Cancer (HRPCA) Market Challenges
    Table 15. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints
    Table 16. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players (2017-2022)
    Table 18. Global Top Hormone Refractory Prostate Cancer (HRPCA) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2021)
    Table 19. Ranking of Global Top Hormone Refractory Prostate Cancer (HRPCA) Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Hormone Refractory Prostate Cancer (HRPCA) Product Solution and Service
    Table 23. Date of Enter into Hormone Refractory Prostate Cancer (HRPCA) Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2017-2022)
    Table 27. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Market Share by Type (2023-2028)
    Table 29. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2017-2022)
    Table 31. Global Hormone Refractory Prostate Cancer (HRPCA) Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Application (2023-2028)
    Table 33. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & (US$ Million)
    Table 34. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028) & (US$ Million)
    Table 35. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & (US$ Million)
    Table 36. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028) & (US$ Million)
    Table 37. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022) & (US$ Million)
    Table 38. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028) & (US$ Million)
    Table 39. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & (US$ Million)
    Table 40. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028) & (US$ Million)
    Table 41. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & (US$ Million)
    Table 42. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028) & (US$ Million)
    Table 43. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022) & (US$ Million)
    Table 44. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028) & (US$ Million)
    Table 45. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & (US$ Million)
    Table 46. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028) & (US$ Million)
    Table 47. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & (US$ Million)
    Table 48. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028) & (US$ Million)
    Table 49. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2022) & (US$ Million)
    Table 50. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2023-2028) & (US$ Million)
    Table 51. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & (US$ Million)
    Table 52. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028) & (US$ Million)
    Table 53. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & (US$ Million)
    Table 54. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028) & (US$ Million)
    Table 55. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022) & (US$ Million)
    Table 56. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028) & (US$ Million)
    Table 57. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2022) & (US$ Million)
    Table 58. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2023-2028) & (US$ Million)
    Table 59. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2022) & (US$ Million)
    Table 60. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2023-2028) & (US$ Million)
    Table 61. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2017-2022) & (US$ Million)
    Table 62. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2023-2028) & (US$ Million)
    Table 63. Astellas Inc Company Details
    Table 64. Astellas Inc Business Overview
    Table 65. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 66. Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million)
    Table 67. Astellas Inc Recent Developments
    Table 68. Sanofi S.A Company Details
    Table 69. Sanofi S.A Business Overview
    Table 70. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 71. Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million)
    Table 72. Sanofi S.A Recent Developments
    Table 73. Dendreon Corporation, Bayer AG Company Details
    Table 74. Dendreon Corporation, Bayer AG Business Overview
    Table 75. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 76. Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million)
    Table 77. Dendreon Corporation, Bayer AG Recent Developments
    Table 78. Johnson & Johnson Company Details
    Table 79. Johnson & Johnson Business Overview
    Table 80. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product
    Table 81. Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million)
    Table 82. Johnson & Johnson Recent Developments
    Table 83. Research Programs/Design for This Report
    Table 84. Key Data Information from Secondary Sources
    Table 85. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type: 2021 VS 2028
    Figure 2. Cytotoxic Agents Features
    Figure 3. Anti-Androgens Features
    Figure 4. Vaccines Features
    Figure 5. Radio-Pharmaceuticals Features
    Figure 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application: 2021 VS 2028
    Figure 7. Hospitals Case Studies
    Figure 8. Ambulatory Surgical Centers Case Studies
    Figure 9. Specialty Clinics Case Studies
    Figure 10. Others Case Studies
    Figure 11. Hormone Refractory Prostate Cancer (HRPCA) Report Years Considered
    Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Region: 2021 VS 2028
    Figure 15. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Players in 2021
    Figure 16. Global Top Hormone Refractory Prostate Cancer (HRPCA) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2021)
    Figure 17. The Top 10 and 5 Players Market Share by Hormone Refractory Prostate Cancer (HRPCA) Revenue in 2021
    Figure 18. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY (2017-2028) & (US$ Million)
    Figure 19. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2028)
    Figure 20. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2028)
    Figure 21. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Country (2017-2028)
    Figure 22. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY (2017-2028) & (US$ Million)
    Figure 25. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2028)
    Figure 26. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2028)
    Figure 27. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Country (2017-2028)
    Figure 28. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. France Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 33. Nordic Countries Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY (2017-2028) & (US$ Million)
    Figure 35. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2028)
    Figure 36. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2028)
    Figure 37. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Region (2017-2028)
    Figure 38. China Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 41. Southeast Asia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. India Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
    Figure 44. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY (2017-2028) & (US$ Million)
    Figure 45. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2028)
    Figure 46. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2028)
    Figure 47. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Country (2017-2028)
    Figure 48. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 49. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY (2017-2028) & (US$ Million)
    Figure 51. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Type (2017-2028)
    Figure 52. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Market Share by Application (2017-2028)
    Figure 53. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Share by Country (2017-2028)
    Figure 54. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 55. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 56. UAE Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 57. Astellas Inc Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
    Figure 58. Sanofi S.A Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
    Figure 59. Dendreon Corporation, Bayer AG Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
    Figure 60. Johnson & Johnson Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022)
    Figure 61. Bottom-up and Top-down Approaches for This Report
    Figure 62. Data Triangulation
    Figure 63. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Frequently Asked Questions
Hormone Refractory Prostate Cancer (HRPCA) report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Hormone Refractory Prostate Cancer (HRPCA) report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Hormone Refractory Prostate Cancer (HRPCA) report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Foam Coatings

Foam Coatings market is segmented by Type and by Application. Players, stakeholders, and other pa ... Read More